CN115666633A - CpG-佐剂的SARS-CoV-2病毒疫苗 - Google Patents

CpG-佐剂的SARS-CoV-2病毒疫苗 Download PDF

Info

Publication number
CN115666633A
CN115666633A CN202180018452.0A CN202180018452A CN115666633A CN 115666633 A CN115666633 A CN 115666633A CN 202180018452 A CN202180018452 A CN 202180018452A CN 115666633 A CN115666633 A CN 115666633A
Authority
CN
China
Prior art keywords
cov
sars
vaccine
inactivated
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018452.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·迈因克
M·莫伦
C·赖尼施
R·西勒奇
C·陶赫尔
J·D·坎贝尔
D·纳瓦克
R·S·詹森
J·海因德尔-乌拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Dynavax Technologies Corp
Original Assignee
Valneva Austria GmbH
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria GmbH, Dynavax Technologies Corp filed Critical Valneva Austria GmbH
Priority claimed from PCT/IB2021/052858 external-priority patent/WO2021176434A1/en
Publication of CN115666633A publication Critical patent/CN115666633A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180018452.0A 2020-04-06 2021-04-06 CpG-佐剂的SARS-CoV-2病毒疫苗 Pending CN115666633A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20168324.0 2020-04-06
EP20202124 2020-10-15
EP20202124.2 2020-10-15
EP20211936 2020-12-04
EP20211936.8 2020-12-04
EP21154645.2 2021-02-01
EP21154645 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
USPCT/US2021/020313 2021-03-01
EP21160933 2021-03-05
EP21160933.4 2021-03-05
PCT/IB2021/052858 WO2021176434A1 (en) 2020-03-01 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Publications (1)

Publication Number Publication Date
CN115666633A true CN115666633A (zh) 2023-01-31

Family

ID=83887208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018452.0A Pending CN115666633A (zh) 2020-04-06 2021-04-06 CpG-佐剂的SARS-CoV-2病毒疫苗

Country Status (4)

Country Link
KR (1) KR20230005814A (ko)
CN (1) CN115666633A (ko)
CA (1) CA3168783A1 (ko)
MX (1) MX2022010781A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116983401A (zh) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432437A (zh) * 2022-01-07 2022-05-06 广东粤港澳大湾区国家纳米科技创新研究院 四氧化三锰颗粒在制备疫苗佐剂中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116983401A (zh) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Also Published As

Publication number Publication date
MX2022010781A (es) 2023-03-09
CA3168783A1 (en) 2021-09-10
KR20230005814A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
CN108697785B (zh) Zika病毒疫苗
CN113151312B (zh) 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用
CN111821433B (zh) mRNA疫苗及其合成方法、试剂盒
CN113185613A (zh) 新型冠状病毒s蛋白及其亚单位疫苗
TWI297040B (en) Recombinant baculovirus and virus-like particle
US11684669B2 (en) CpG-adjuvanted SARS-CoV-2 virus vaccine
CN112575008B (zh) 编码新型冠状病毒的结构蛋白的核酸分子以及新型冠状病毒疫苗
KR20170102905A (ko) 신규 다가 나노입자 기반 백신
CN113736801B (zh) mRNA及包含其的新冠病毒mRNA疫苗
CN109069616A (zh) 稳定化的可溶性融合前rsv f蛋白
CN113321739A (zh) 一种covid-19亚单位疫苗及其制备方法与应用
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN115666633A (zh) CpG-佐剂的SARS-CoV-2病毒疫苗
KR20230012583A (ko) 합성 변형된 백시니아 앙카라 (sMVA) 기반 코로나바이러스 백신
CN114989308B (zh) 新冠病毒嵌合核酸疫苗及其用途
CN112175913A (zh) SARS-CoV-2减毒株及其在预防新冠肺炎中的应用
WO2021222639A2 (en) Recombinant human metapneumovirus f proteins and their use
WO2024114542A1 (zh) 痘病毒多抗原嵌合疫苗及其用途
CN116410992A (zh) 预防和/或治疗新型冠状病毒的mRNA、疫苗及其制备方法和应用
CN115678906A (zh) 经优化的新冠病毒嵌合核酸疫苗及其用途
KR20220164500A (ko) 불활성화된 SARS-CoV-2 바이러스 백신
CN115322247A (zh) 一种新型冠状病毒受体结合区电荷突变体抗原及应用
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
KR20210005090A (ko) 키메라 벡터
RU2813150C2 (ru) Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination